LabStyle Innovations Featured on the Cover of Opportunist Magazine

Q&A with Managing Editor includes in-depth interview about LabStyle's leadership in the diabetes and digital health industries

Jul 22, 2015, 12:42 ET from LabStyle Innovations Corp.

CAESAREA, Israel, July 22, 2015 /PRNewswire/ --

LabStyle Innovations Corp. (DRIO), today announced that its President & CEO Erez Raphael is featured on the cover of the July 21 issue of Opportunist Magazine. In the feature article Raphael talks with Opportunist's Managing Editor Leslie Stone about LabStyle's Dario™ Diabetes Management Solution, an all-in-one glucose meter and cloud-based mobile diabetes management platform. Stone asks Raphael a range of compelling and insightful questions about how the Dario is transforming the diabetes treatment market and the future of LifeStyle Innovations.

In response to Stone's questions about Raphael's message to investors, he responds, "First, when you look at the overall glucose monitoring side of the medical industry in general, it represents a $12B market. Likewise, the market for mobile apps is huge. Up until we came along, whenever new technology was developed for diabetes management it was all on a dedicated device. This is the first time someone is providing something that is cost effective and I think we can catch a very big portion of this market."

To read the article in full, please visit:

http://opportunistmagazine.com/turn-your-smartphone-into-a-glucose-meter/

About LabStyle Innovations  

LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ Diabetes Management Solution. Dario™ empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket.  With access to both real-time and historical blood glucose data, Dario™ is designed to spot patterns, recommend the right treatments and support behavior change efforts.

Dario™ is a platform that combines an all-in-one, blood glucose meter, smart phone application (iOS & Android), website application and treatment tools to support more proactive and better informed decisions by patients, doctors and healthcare systems. The stylish and compact self-monitoring system combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter. LabStyle Innovations is led by an experienced management team with vast software, medical device and technology experience and is guided by a world class board of directors and scientific advisory board. For more information: http://www.myDario.com and http://myDario.investorroom.com .

Cautionary Note Regarding Forward-Looking Statements 

This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Contacts:
Press and Investor Relations
Brenda Zeitlin
LabStyle Innovations
+1-800-896-9062
Brenda@mydario.com

SOURCE LabStyle Innovations Corp.